HC Wainwright Has Negative Estimate for RYTM FY2025 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Stock analysts at HC Wainwright reduced their FY2025 earnings per share (EPS) estimates for Rhythm Pharmaceuticals in a report issued on Sunday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($3.09) per share for the year, down from their prior forecast of ($2.86). HC Wainwright currently has a “Buy” rating and a $110.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q4 2025 earnings at ($0.73) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.59) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.34) EPS and FY2026 earnings at ($2.03) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.10). Rhythm Pharmaceuticals had a negative net margin of 117.13% and a negative return on equity of 1,831.43%. The company had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.71 million.

Other analysts also recently issued reports about the stock. JMP Securities upped their price objective on shares of Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a “market outperform” rating in a report on Thursday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research note on Wednesday, October 8th. The Goldman Sachs Group cut their price objective on Rhythm Pharmaceuticals from $157.00 to $139.00 and set a “buy” rating for the company in a research report on Friday, October 17th. Wall Street Zen lowered Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Needham & Company LLC upped their price target on Rhythm Pharmaceuticals from $95.00 to $122.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $113.23.

Rhythm Pharmaceuticals Stock Up 2.3%

Shares of RYTM stock opened at $99.86 on Wednesday. Rhythm Pharmaceuticals has a 12 month low of $45.90 and a 12 month high of $116.00. The company has a market cap of $6.66 billion, a PE ratio of -33.18 and a beta of 2.12. The business’s 50 day moving average is $102.80 and its two-hundred day moving average is $85.56.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in RYTM. Smartleaf Asset Management LLC grew its stake in shares of Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after purchasing an additional 141 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Rhythm Pharmaceuticals in the 1st quarter valued at $34,000. Farther Finance Advisors LLC grew its position in Rhythm Pharmaceuticals by 1,110.3% in the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock valued at $35,000 after acquiring an additional 322 shares during the period. Optiver Holding B.V. grew its position in Rhythm Pharmaceuticals by 65.2% in the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock valued at $37,000 after acquiring an additional 144 shares during the period. Finally, Osaic Holdings Inc. raised its stake in Rhythm Pharmaceuticals by 65.9% during the second quarter. Osaic Holdings Inc. now owns 979 shares of the company’s stock worth $62,000 after acquiring an additional 389 shares in the last quarter.

Insider Activity

In other news, insider Joseph Shulman sold 14,437 shares of the firm’s stock in a transaction dated Thursday, October 16th. The shares were sold at an average price of $112.03, for a total transaction of $1,617,377.11. Following the completion of the transaction, the insider directly owned 8,509 shares of the company’s stock, valued at approximately $953,263.27. This trade represents a 62.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 31,188 shares of company stock valued at $3,483,583. Corporate insiders own 6.10% of the company’s stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.